School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
HSE Addiction Services, Dublin, Ireland.
Addiction. 2020 Oct;115(10):1867-1877. doi: 10.1111/add.15004. Epub 2020 Mar 27.
To examine the risk of mortality associated with interruptions to the continuity of methadone maintenance treatment (MMT), including transfers between services, in opioid-dependent individuals attending specialist addiction services.
Retrospective cohort study using addiction services and primary care dispensing records, the National Methadone Register and National Drug-Related Death Index (NDRDI).
Geographically defined population in Dublin, Ireland.
A total of 2899 people prescribed and dispensed methadone in specialist addiction services between January 2010 and December 2015. There were five exposure groups: weeks 1-4 following transfer between treatment providers; weeks 1-4 out of treatment; weeks 5-52 out of treatment; weeks 1-4 of treatment initiation; and weeks 5+ of continuous treatment (reference category).
Primary outcome: drug-related poisoning (DRP) deaths. Secondary outcome: all-cause mortality (ACM). Mortality rates calculated by dividing number of deaths (DRP; ACM) in exposure groups by person-years exposure. Unadjusted and adjusted Poisson regression (covariates age, sex, incarceration, methadone dose and comorbidities) estimated differences in mortality rates.
There were 154 ACM deaths, 55 (35.7%) identified as DRP deaths. No deaths were observed in the first month following transfer between treatment providers. The risk of DRP mortality was highest in weeks 1-4 out of treatment [adjusted relative risk (aRR = 4.04, 95% confidence interval (CI) = 1.43-11.43, P = 0.009] and weeks 1-4 of treatment initiation (ARR = 3.4, 95% CI = 1.2-9.64, P = 0.02). Similarly, risk of ACM was highest in weeks 1-4 out of treatment (ARR = 11.78, 95% CI = 7.73-17.94, P < 0.001), weeks 1-4 of treatment initiation (aRR = 5.11, 95% CI = 2.95-8.83, P < 0.001) and weeks 5-52 off treatment (aRR = 2.04, 95% CI = 1.2-3.47, P = 0.009).
Interruptions to the continuity of methadone maintenance treatment by treatment provider do not appear to be periods of risk for drug-related poisoning or all-cause mortality deaths. Risk of drug related poisoning and all-cause mortality deaths appears to be greatest during the first 4 weeks of treatment initiation/re-initiation and after treatment cessation.
探讨在接受专门成瘾服务的阿片类药物依赖者中,美沙酮维持治疗(MMT)连续性中断(包括服务间转介)与死亡率之间的关系。
利用成瘾服务和初级保健配药记录、国家美沙酮登记处和国家药物相关死亡指数(NDRDI)进行回顾性队列研究。
爱尔兰都柏林的一个地理定义的人群。
2010 年 1 月至 2015 年 12 月期间,共有 2899 名在专门成瘾服务中接受和配给美沙酮的人。共有五个暴露组:提供者之间治疗转介后的第 1-4 周;治疗外的第 1-4 周;治疗外的第 5-52 周;治疗开始的第 1-4 周;和连续治疗的第 5 周及以上(参考类别)。
主要结局:与药物相关的中毒(DRP)死亡。次要结局:全因死亡率(ACM)。通过将暴露组中的死亡人数(DRP;ACM)除以人年暴露数来计算死亡率。未调整和调整后的泊松回归(协变量为年龄、性别、监禁、美沙酮剂量和合并症)估计了死亡率的差异。
共发生 154 例 ACM 死亡,55 例(35.7%)确定为 DRP 死亡。在提供者之间治疗转介后的第一个月内没有观察到死亡。在治疗外的第 1-4 周(调整后的相对风险[aRR]为 4.04,95%置信区间[CI]为 1.43-11.43,P=0.009)和治疗开始的第 1-4 周(aRR 为 3.4,95%CI 为 1.2-9.64,P=0.02),DRP 死亡率风险最高。同样,治疗外的第 1-4 周(ARR 为 11.78,95%CI 为 7.73-17.94,P<0.001)、治疗开始的第 1-4 周(aRR 为 5.11,95%CI 为 2.95-8.83,P<0.001)和治疗外的第 5-52 周(aRR 为 2.04,95%CI 为 1.2-3.47,P=0.009),ACM 风险最高。
提供者之间美沙酮维持治疗连续性中断似乎不是与药物相关的中毒或全因死亡率死亡的风险期。与药物相关的中毒和全因死亡率死亡的风险似乎在治疗开始/重新开始的最初 4 周内以及治疗结束后最大。